Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

EST Cathie Wood’s ARK Investment buys 54.4K shares of Qualcomm (QCOM) todayMaximize Your Portfolio with Data Driven Insights:Leverage the ...

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The Dow Jones Industrial Average ( ^DJI) fell 0.3%. Meanwhile, the S&P 500 ( ^GSPC) rose more than 0.3% while the tech-heavy ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Wall Street is drifting as drops for Ford Motor and Qualcomm work against buoyant fashion and cigarette stocks. The S&P 500 slipped 0.1% Thursday following healthy gains for stock markets ...

Investing.com-- The S&P 500 gave up gains Thursday, as investors assessed a deluge of corporate earnings as well as more ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...